Business
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis Conf
About this update from Altimmune, Inc.
[{"type":"image","alt":"Altimmune, Inc","displaySize":"","headline":null,"caption":"Altimmune, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gY.Kxe7ML79dI0xW5370RA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009","width":150,"height":82}},"lazy":false},{"type":"text","content":"Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint","length":153,"tagName":"p"},{"type":"text","content":"Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing","length":79,"tagName":"p"},{"type":"text","content":"Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate ","length":125,"tagName":"p"},{"type":"text","content":"End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis","length":140,"tagName":"p"},{"type":"text","content":"Conference call to be held today at 8:00 a.m. ET","length":48,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks.","length":416,"tagName":"p"},{"type":"text","content":"Topline 48-week data from the IMPACT trial showed that treatment with pemvidutide achieved statistically significant improvements across treatment arms in key non-invasive tests (NITs), including Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM), versus placebo. Importantly, these data exhibited continued reductions from week 24 and provide evidence of continued improvement in antifibrotic activity with both treatment doses. These are well-established markers of fibrosis and hepatic inflammation and are strongly associated with...